H.C. Wainwright reiterated a ‘Buy’ rating on MannKind with an $11 price target after the company’s update. ・The firm said it ...

Estimated YUTREPIA™ net product sales of approximately $90.1 million in the fourth quarter and $148.3 million for full-year 2025Received more ...

Biopharmaceutical company Liquidia has received tentative approval from the US Food and Drug Administration (FDA) for YUTREPIA (treprostinil) inhalation powder to treat pulmonary arterial hypertension ...

Liquidia (LQDA) on Friday announced preliminary, unaudited full-year 2025 net product sales of YUTREPIA™ (treprostinil) inhalation powder, estimating $90.1 million in Q4 and $148.3 million for the ...

MORRISVILLE, N.C., May 23, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation, a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today ...

- First and Only Digital Rescue Inhaler with Built-In Sensors Now Available By Prescription to Patients in the U.S. TEL AVIV & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Respiratory, LLC., a U.S.

March 2, 2006 — The US Food and Drug Administration (FDA) has approved orphan drug status for amphotericin B inhalation powder in the prevention of pulmonary fungal infections in patients at risk for ...

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Lupin’s 18 µg capsules of tiotropium bromide inhalation powder, according to a manufacturer ...

FDA's approval of YUTREPIA paves the way for prescribers to add a new treatment option for patients with PAH and PH-ILD YUTREPIA is designed to enhance deep-lung delivery with an easy-to-use device ...